{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Very good partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Complete response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"ORR includes Partial Response (PR) + Very Good Partial Response (VGPR) + Complete Response (CR)\n\nResponse will be assessed per the International Myeloma Working Group (IMWG) Response Criteria.","groups":[{"description":"Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0","id":"OG000","title":"V-BEAM + Stem Cell Infusion"}],"paramType":"NUMBER","populationDescription":"Two participants without evaluable responses due to early mortality were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"3 months following Day +100 visit","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"participants"}